Home SVCC                                                  Area: English - Español - Português

To Evaluate the use of Edta, Calcium
Chelating, in the Coronary Heart
Disease Treatment

Peña Quian, Yamilé; Batista C, Juan F; Coca Marco, A;
Stusser, Rodolfo; Ruibal L, Antonio; Rochela V, Luis M.

Center for Clinical Research, Havana, Cuba

SUMMARY
Introduction: Last decades, it has been to achieve results in coronary heart disease treatments with calcium chelating. The EDTA is the more used drug in the world. Some works had demonstrated that, the EDTA administered by means of arterial infusion acts over calcium arterial deposit, which they are common component of the complicated ateroma plate, achieving the reduction of extent of it.
Objectives: To study the existence or not of remission of the coronary heart disease after the treatment with EDTA.
Material and Methods: Twelve patients were included, eleven men and one woman. All of them were determined risk factors, kind of coronary artery disease and treatment. All patients were study by: rest electrocardiogram, ergometric evaluation and heart perfusion SPECT. They were subjected to treatment, it consist of the administration through arterial infusion of EDTA (600 mg/Kg/min) diluted in 300 ml of dextrose (5%) with a duration from 4 to 5 hours during 25 sessions. Finished the treatment, all patients were evaluated again according to the clinical manifestations, treatment, electrocardiogram and the heart perfusion SPECT results.
Results: Three patients had significant improvements, in the clinic and heart perfusion (an increase more than 10% of perfusion for studied segment). Two patients referred to feel clinically better and showed non-significant improvements in the heart perfusion (an increase smaller than 10% of the perfusion for segment). Six patients stayed without changes and only one patient presented non-significant worsening.
In five patients, it could decrease the amount of drugs to use in the treatment.
Conclusion: The EDTA could be effective in the treatment of the coronary heart disease in certain group of patient well selected according to risk factor and vascular complications.

Top

INTRODUCTION
   
The heart diseases, specifically the coronary heart disease, occupy the first place inside the first 10 causes of death to world level (1). The anatomical substrate of base is the arteriosclerosis.

   Last decades, it has been to achieve results in coronary heart disease treatments with calcium chelating. The EDTA (Sour Ethylene Diamino Tetracético) is the more used drug in the world (2). Some works had demonstrated that, the EDTA administered by means of arterial infusion acts over calcium arterial deposits, which they are common component of the complicated ateroma plate, achieving the reduction of extent of it (3-6).

   This, chemical quelante, attracts and eliminates the freedom calcium in the blood, obligating to the organism to obtain deposit calcium, like the arteries, and to return it to the blood for its transport to the cells of the body.

   As a result of the elimination of the calcium deposits, the cholesterol and other fatty substances in the arteries are ¨become soft¨ and they are again exposed to the action of the blood. This metabolizes these fatty deposits that have been to the overdraft, splitting the big molecules in other smaller and yielding, with this process, energy and waste material. Consequently, the blocked arteries are essentially free.

   The EDTA doesn't dissolve the sanguine calcium bound to the proteins, on the other hand, the calcium of the ateroma plate is low fixed (only electrostatic force) and therefore it passes easily to the blood flow, the calcium of the bones and the teeth are more bound to the proteins.

   The international results of the chelation therapy are controversial and the studies carried out throw different conclusions (7-14).

OBJETIVES
   1. To study the existence or not of the remission of the coronary heart disease after the treatment with EDTA, using a non invasive method, single photon emission computer tomography (SPECT).

MATERIALS AND METHODS
Patient
   Twelve patients were included, which were selected according to inclusion criterion of coronary heart disease, eleven of them was the masculine and one feminine, all of them were determined risk factors, kind of coronary artery disease and treatment. All patients were study by: rest electrocardiogram, ergometric evaluation and heart perfusion SPECT.

TREATMENT
   They were subjected to treatment, it consist of the administration through arterial infusion of EDTA (600 mg/Kg/min) diluted in 300 ml of dextrose (5%) with duration from 4 to 5 hours during 25 sessions. Finished the treatment, all patients were evaluated again according to the clinical manifestations, treatment, electrocardiogram and the heart perfusion SPECT results.

RESULTS AND DISCUSSION
   As you it can appreciate in the table 1, in our study exist a remarkable prevalence of the masculine sex, which is agreement with that reported in the world reference, all patients were in ages between 35 and 65 years old.

   All the patients presented coronary risk factors (table 2), among them the more frequents is smoking habit, existing someone with more one coronary risk factor associated to the coronary heart disease.

   The 25% of the 12 studied patients suffered acute myocardial stroke, the rest presented different types of angina with symptoms in the moment of the treatment with EDTA (table 3).

   Once received the treatment, the 75% referred improvement of the such clinical symptoms as intensity and duration of the pain, the number of nitroglycerines necessary in the day, inclusive in 5 patients, it could decrease the number of medications to stay without symptoms. (table 4)

   The 25% of the patients presented significant improvement (table 5), that is mean, an increase of 10% of the myocardial perfusion in those segments that presented hypo-perfusion in the basal study. In this result, only patient had worsening of the myocardial perfusion, being this considered not significant since the decrease of the perfusion was smaller than 10% the basal study, in this case, the patient also referred not abandon to important risk factors as smoking habit, eat plentiful and with animal fat among others.

   In the results (table 6), we can observe to that in the patients with clinical improvement and significant improvement in the results of SPECT (figure 1) had associated only risk factor, which never was smoking habit. The patients that presented more one risk factor or association of risk factors with previous acute myocardial stroke, in most of the cases, they stayed without change or worsened.



CONCLUSION
   The EDTA could be effective in the treatment of the coronary heart disease in certain group of patient well selected according to risk factor and vascular complications

REFERENCES

1. World Health Organization. The World Health Report Geneva 2000; 164-168.

2. Godfrey ME. EDTA chelation as a treatment of arteriosclerosis. N Z Med J. 1990; 103:162-163.

3. Cranton EM. Protocol of the American College of Advancement in Medicine for the Safe and Effective Administration of EDTA Chelation Therapy. Laguna Hills, Calif; American College of Advancement in Medicine; 1989.

4. Casdorph RH, Farr CH. EDTA chelation therapy lll: treatment of peripheral arterial occlusion, an alternative to amputation. J Hol Med. 1983; 5:3-15.

5. Sloth-Nielsen J, Guldager B, Mouitzen C, Lund EB, Egeblad M, Norregaard O, Jorgenson SL, Jelnes R. Arteriographic findings in EDTA chelation therapy on peripheral arteriosclerosis. Am J Surg.1991; 162:122-125.

6. MGuldager B, Jelnes R, Jorgense SJ, Nielsen JS, Klaerke A, Mogense K, Larsen KE, Reimer E, Holm J, Ottense S. EDTA treatment of intermittent claudication: a double-blind, placebo controlled study. J Intern Med. 1992; 231:261-267.

7. Diagnostic and therapeutic technology assessment: chelation therapy. JAMA. 1983; 250:672.

8. Scott PJ. Chelation therapy: evolution or devolution of nostrum? N Z Med J. 1988; 101:109-110.

9. Scott PJ. Chelation therapy for degenerative vascular disease. N Z Med J. 1982; 95:538-539.

10. Robinson D. Chelation therapy N Z Med J. 1982; 95:750. Letter.

11. Soffer A. Chelation clinics: an abuse of the physician's freedom of choice. Arch Intern Med. 1984; 144:1741-1742.

12. Ernst E.. Chelation therapy for coronary heart desease: An overview of all clinical investigation. Am Heart J. 2000: July; 140(1):139-41

13. Andre M, Van Rij, Clive Salomon and col. Chelation Therapy for intermittent claudication. Circulation vol. 90, No 3 September 1994.

14. JA Rumberger JF Breen, LA Schwartz. Electron Beam Computed Tomography and Coronary Artery Disease: Scanning for Coronary Artery Calcification Mayo Clinic Pro
ceedings 71. 1996; (4): 369-377.

 

Top

Your questions, contributions and commentaries will be
answered by the authors in the Ischemic Heart Disease list.
Please fill in the form (in Spanish, Portuguese or English) and press the "Send" button.

Question,
contribution
or commentary
:
Name and Surname:
Country:
E-Mail address:

Top


2nd Virtual Congress of Cardiology

Dr. Florencio Garófalo
Steering Committee
President
Dr. Raúl Bretal
Scientific Committee
President
Dr. Armando Pacher
Technical Committee - CETIFAC
President
fgaro@fac.org.ar
fgaro@satlink.com
rbretal@fac.org.ar
rbretal@netverk.com.ar
apacher@fac.org.ar
apacher@satlink.com

Copyright© 1999-2001 Argentine Federation of Cardiology
All rights reserved

 

This company contributed to the Congress: